This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Connell, J. B. Articles by Robinson, J. A. Search for Related Content PubMed PubMed Citation Articles by O'Connell, J. B. Articles by Robinson, J. A.

Circulation, Vol 73, 353-359, Copyright © 1986 by American Heart Association

ARTICLES

The effects of cyclosporine on acute murine Coxsackie B3 myocarditis

JB O'Connell, EA Reap and JA Robinson

The effects of the immunosuppressant drug cyclosporine were studied in the murine model of Coxsackie B3 myocarditis. Ten BALB/c mice, given daily cyclosporine (15 mg/kg) intraperitoneally but not infected, were normal in all respects after 2 weeks. All 32 BALB/c mice infected, but given no cyclosporine, survived and had moderate myocardial mononuclear infiltrates and minimal necrosis at 7 and 14 days. In contrast, 24 mice concurrently infected and given cyclosporine had a high mortality rate (75%) and a significantly attenuated mononuclear infiltrate in the presence of enhanced necrosis when compared with control infected mice. Sixteen mice started on the drug 1 week after infection had a lower mortality rate (55%), but very similar histologic abnormalities. In contrast to negligible or no virus in the hearts of infected mice that were not given cyclosporine, drug treated, infected groups had easily detectable virus in their hearts 14 days after infection. An identical study in Swiss ICR mice yielded similar results. Cyclosporine, when given early during acute murine Coxsackie B3 myocarditis, causes a significant increase in myocardial necrosis and mortality, possibly secondary to enhanced viral survival.

This article has been cited by other articles:

				B. W. Duncan, D. J. Bohn, A. M. Atz, J. W. French, P. C. Laussen, and D. L. Wessel Mechanical circulatory support for the treatment of children with acute fulminant myocarditis J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 440 - 448. [Abstract] [Full Text] [PDF]

				T. Miyamoto, A. Matsumori, M.-W. Hwang, R. Nishio, H. Ito, and S. Sasayama Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1713 - 1718. [Abstract] [Full Text] [PDF]

				K J Lee, B W McCrindle, D J Bohn, G J Wilson, G P Taylor, R M Freedom, J F Smallhorn, and L N Benson Clinical outcomes of acute myocarditis in childhood Heart, August 1, 1999; 82(2): 226 - 233. [Abstract] [Full Text] [PDF]

				G. Grassl, C. L. Pummerer, I. Horak, and N. Neu Induction of Autoimmune Myocarditis in Interleukin-2–Deficient Mice Circulation, April 1, 1997; 95(7): 1773 - 1776. [Abstract] [Full Text]

				H. Takada, C. Kishimoto, and Y. Hiraoka Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects Circulation, September 15, 1995; 92(6): 1604 - 1611. [Abstract] [Full Text]

				M. Kodama, S. Zhang, H. Hanawa, M. Saeki, T. Inomata, K. Suzuki, S. Koyama, and A. Shibata Effects of 15-Deoxyspergualin on Experimental Autoimmune Giant Cell Myocarditis of the Rat Circulation, February 15, 1995; 91(4): 1116 - 1122. [Abstract] [Full Text]

				L. G. Lange and G. F. Schreiner Immune Mechanisms of Cardiac Disease N. Engl. J. Med., April 21, 1994; 330(16): 1129 - 1135. [Full Text]